These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 31008931)

  • 21. The Clinical Significance and Prognostic Value of ALDH1 Expression in Non-small Cell Lung Cancer: A Systematic Review and Meta-analysis.
    Li D; Cao Y; Luo CW; Zhang LP; Zou YB
    Recent Pat Anticancer Drug Discov; 2024; 19(5):599-609. PubMed ID: 37818578
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MicroRNA-138 acts as a tumor suppressor in non small cell lung cancer via targeting YAP1.
    Xiao L; Zhou H; Li XP; Chen J; Fang C; Mao CX; Cui JJ; Zhang W; Zhou HH; Yin JY; Liu ZQ
    Oncotarget; 2016 Jun; 7(26):40038-40046. PubMed ID: 27223073
    [TBL] [Abstract][Full Text] [Related]  

  • 23. LncRNA NNT-AS1 promotes non-small cell lung cancer progression through regulating miR-22-3p/YAP1 axis.
    He W; Zhang Y; Xia S
    Thorac Cancer; 2020 Mar; 11(3):549-560. PubMed ID: 31923353
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The association between the expression of nuclear Yes-associated protein 1 (YAP1) and p53 protein expression profile in breast cancer patients.
    Cha YJ; Kim D; Bae SJ; Ahn SG; Jeong J; Cho MK; Paik PS; Yoo TK; Park WC; Yoon CI
    PLoS One; 2021; 16(5):e0250986. PubMed ID: 33970925
    [TBL] [Abstract][Full Text] [Related]  

  • 25. KRAS mutation is a weak, but valid predictor for poor prognosis and treatment outcomes in NSCLC: A meta-analysis of 41 studies.
    Pan W; Yang Y; Zhu H; Zhang Y; Zhou R; Sun X
    Oncotarget; 2016 Feb; 7(7):8373-88. PubMed ID: 26840022
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of lactate deshydrogenase levels on non-small cell lung cancer prognosis: a meta-analysis.
    Gong T; Liu J; Jiang J; Zhai YF; Wu CM; Ma C; Wen BL; Yan XY; Zhang X; Wang DM; Lu Q; Qu YL
    Cell Mol Biol (Noisy-le-grand); 2019 Jan; 65(1):89-93. PubMed ID: 30782303
    [TBL] [Abstract][Full Text] [Related]  

  • 27. YAP1 amplification as a prognostic factor of definitive chemoradiotherapy in nonsurgical esophageal squamous cell carcinoma.
    Dai H; Shao YW; Tong X; Wu X; Pang J; Feng A; Yang Z
    Cancer Med; 2020 Mar; 9(5):1628-1637. PubMed ID: 31851786
    [TBL] [Abstract][Full Text] [Related]  

  • 28. YAP1 contributes to NSCLC invasion and migration by promoting Slug transcription via the transcription co-factor TEAD.
    Yu M; Chen Y; Li X; Yang R; Zhang L; Huangfu L; Zheng N; Zhao X; Lv L; Hong Y; Liang H; Shan H
    Cell Death Dis; 2018 May; 9(5):464. PubMed ID: 29700328
    [TBL] [Abstract][Full Text] [Related]  

  • 29. KRAS mutation as a prognostic factor and predictive factor in advanced/metastatic non-small cell lung cancer: A systematic literature review and meta-analysis.
    Goulding RE; Chenoweth M; Carter GC; Boye ME; Sheffield KM; John WJ; Leusch MS; Muehlenbein CE; Li L; Jen MH; Rojubally A; Jansen J; Druyts E
    Cancer Treat Res Commun; 2020; 24():100200. PubMed ID: 32750661
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic and clinicopathological significance of long noncoding RNA MALAT-1 expression in patients with non-small cell lung cancer: A meta-analysis.
    Liu X; Huang G; Zhang J; Zhang L; Liang Z
    PLoS One; 2020; 15(10):e0240321. PubMed ID: 33052949
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cytoplasmic YAP expression is associated with prolonged survival in patients with lung adenocarcinomas and epidermal growth factor receptor tyrosine kinase inhibitor treatment.
    Sun PL; Kim JE; Yoo SB; Kim H; Jin Y; Jheon S; Kim K; Lee CT; Chung JH
    Ann Surg Oncol; 2014 Dec; 21 Suppl 4():S610-8. PubMed ID: 24770679
    [TBL] [Abstract][Full Text] [Related]  

  • 32. EGFR inhibitors as adjuvant therapy for resected non-small cell lung cancer harboring EGFR mutations.
    Tang W; Li X; Xie X; Sun X; Liu J; Zhang J; Wang C; Yu J; Xie P
    Lung Cancer; 2019 Oct; 136():6-14. PubMed ID: 31421260
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The relationship between blood-based tumor mutation burden level and efficacy of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.
    Ba H; Liu L; Peng Q; Chen J; Zhu YD
    BMC Cancer; 2021 Nov; 21(1):1220. PubMed ID: 34774004
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Intercalated Combination of Chemotherapy and EGFR-TKIs versus Chemotherapy Alone in the First-line Treatment of Advanced Non-small Cell Lung Cancer: A Meta-analysis].
    Hong C; Mei T; Wang J
    Zhongguo Fei Ai Za Zhi; 2016 Dec; 19(12):837-846. PubMed ID: 27978869
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of genetic alterations associated with primary resistance to EGFR-TKIs in advanced non-small-cell lung cancer patients with EGFR sensitive mutations.
    Wang F; Diao XY; Zhang X; Shao Q; Feng YF; An X; Wang HY
    Cancer Commun (Lond); 2019 Mar; 39(1):7. PubMed ID: 30823937
    [TBL] [Abstract][Full Text] [Related]  

  • 36. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
    Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic Role of EGFR/p-EGFR in Patients With Nasopharyngeal Carcinoma: A Meta-Analysis.
    Chen X; Liang R; Lai L; Chen K; Zhu X
    Front Oncol; 2021; 11():697369. PubMed ID: 34490092
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anaplastic lymphoma kinase gene rearrangement predicts better prognosis in NSCLC patients: A meta-analysis.
    Wang Z; Yang H; Luo S; Liu B; Zhang N; Li L; Zhou S; Shen R; Xie X
    Lung Cancer; 2017 Oct; 112():1-9. PubMed ID: 29191580
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of Yes-associated protein 1 and its clinical significance in ovarian serous cystadenocarcinoma.
    Cho SY; Kim K; Park MS; Jang MY; Choi YH; Han S; Shin HM; Chung C; Han HY; Yang JB; Ko YB; Yoo HJ
    Oncol Rep; 2017 May; 37(5):2620-2632. PubMed ID: 28339095
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer Harboring Wild-type Epidermal Growth Factor Receptor: A Meta-analysis of 25 RCTs.
    Sheng Z; Zhang Y
    Am J Clin Oncol; 2017 Aug; 40(4):362-369. PubMed ID: 25647830
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.